| (19) |
 |
|
(11) |
EP 1 609 473 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
published in accordance with Art. 158(3) EPC |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
05.07.2006 Bulletin 2006/27 |
| (43) |
Date of publication: |
|
28.12.2005 Bulletin 2005/52 |
| (22) |
Date of filing: 29.03.2004 |
|
| (51) |
International Patent Classification (IPC):
|
| (86) |
International application number: |
|
PCT/CN2004/000281 |
| (87) |
International publication number: |
|
WO 2004/084916 (07.10.2004 Gazette 2004/41) |
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
|
| (30) |
Priority: |
27.03.2003 CN 03108280
|
| (71) |
Applicants: |
|
- Third Military Medical University Chinese People's
Liberation Army P.R. of China
Chongqing 400038 (CN)
- Bio-Wave Institute of Suzhou Hi-Tech New District
Corporation, Ltd
Jiangsu 215011 (CN)
- Beijing Sino-Hongkong Dafu Science & Technology of
Biowave Co., Ltd.
Beijing 101200 (CN)
|
|
| (72) |
Inventors: |
|
- XU, Qiwang,
No. 30 Gaotanyan Street
Chongqing 400038 (CN)
- LIU, Junkang,
No. 30 Gaotanyan Street
Chongqing 400038 (CN)
- YUAN, Zetao,
NO. 30 Gaotanyan Street
Chongqing 400038 (CN)
|
| (74) |
Representative: Neunert, Peter Andreas |
|
Patentanwälte
Westphal, Mussgnug & Partner
Am Riettor 5
78048 Villingen-Schwenningen
78048 Villingen-Schwenningen (DE) |
|
| |
|
| (54) |
USE OF ACETYL-D-AMINOGLYCOSAMINE IN TREATMENT OF LOCAL LESIONS AND SYSTEMATIC SYMPTOMS
RELATED TO INFECTIONS OF VIRUS OR BACTERIA |
(57) The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically
acceptable salts thereof in the manufacture of a medicament for treating local lesions
or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation
comprising N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof as
active component is capable of controlling systematic toxic symptoms caused by infections
of virus and bacteria and local and systematic lesions caused by endotoxins and exotoxins,
and exhibits an excellence rate of 90%.